Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glabellar Lines Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014635
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

NCT03004248
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines

NCT01447342
View directory record Official record
Conditions
Facial Wrinkles, Skin Aging
Interventions
Cryo-Touch II
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
30 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Beverly Hills, California • Redwood City, California • Roseville, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

NCT06246552
View directory record Official record
Conditions
Glabellar Lines
Interventions
JTM201, Placebo
Biological
Lead sponsor
Jetema USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

NCT04225260
View directory record Official record
Conditions
Glabellar Lines, Lateral Canthal Lines
Interventions
botulinum toxin neuromodulator
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

NCT05013424
View directory record Official record
Conditions
Glabellar Lines
Interventions
Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Glendale, Arizona • Coral Gables, Florida • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

NCT01391312
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin Type A, normal saline (placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
East Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 2, 2026, 4:23 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

NCT04715048
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
PrabotulinumtoxinA, Onabotulinum toxin A
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

NCT05320393
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
Drug
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 2, 2026, 4:23 AM EDT
Terminated No phase listed Observational

Longitudinal Evaluation and Real-world Evidence of NT201

NCT05222607
View directory record Official record
Conditions
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

NCT00770211
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

NCT05129319
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
prabotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03960957
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA, Placebo
Biological · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
11
States / cities
Redondo Beach, California • San Diego, California • Westport, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

NCT04763265
View directory record Official record
Conditions
Frown Lines
Interventions
Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
Biological
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Santa Monica, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

NCT05496335
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, BOTOX, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Newport Beach, California • San Diego, California • Greenwood Village, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

NCT04157686
View directory record Official record
Conditions
Glabellar Lines, Lateral Canthal Lines
Interventions
MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
19 Years and older
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • Newport Beach, California • Solana Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

NCT03985982
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014622
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

AI-09 In Subjects With Glabellar Lines, GL-101

NCT05565950
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AI-09, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
20 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Boca Raton, Florida • Miami, Florida • New Brighton, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01189760
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions
onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

NCT04259086
View directory record Official record
Conditions
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Interventions
DaxibotulinumtoxinA for injection
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Manhattan Beach, California • San Diego, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01224015
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions
normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
Drug · Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 2, 2026, 4:23 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

NCT05083286
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Encino, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 2, 2026, 4:23 AM EDT